(3S,4S)-2-oxo-4-phenylpyrrolidine-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3S,4S)-2-oxo-4-phenylpyrrolidine-3-carboxylic acid
• 化学式: C₁₁H₁₁NO₃
• 分子量: 205.213
• InChiKey: UOQRZCNCICUPJO-BDAKNGLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  thioacetic acid S-((-S)-6-amino-6-phenylcarbamoyl-hexyl) ester trifluoroacetate 、 (3S,4S)-2-oxo-4-phenylpyrrolidine-3-carboxylic acid 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 thioacetic acid S-{(S)-6-[((3S,4S)-2-oxo-4-phenylpyrrolidine-3-carbonyl)amino]-6-phenylcarbamoylhexyl} ester
  参考文献：
  名称：

  ST7612AA1, a Thioacetate-ω(γ-lactam carboxamide) Derivative Selected from a Novel Generation of Oral HDAC Inhibitors

  摘要：

  A systematic study of medicinal chemistry aimed at identifying a new generation of HDAC inhibitors, through the introduction of a thiol zinc-binding group (ZBG) and of an amide-lactam in the ?-position of the polyethylene chain of the vorinostat scaffold, allowed the selection of a new class of potent pan-HDAC inhibitors (pan-HDACis). Simple, highly versatile, and efficient synthetic approaches were used to synthesize a library of these new derivatives, which were then submitted to a screening for HDAC inhibition as well as to a preliminary in vitro assessment of their antiproliferative activity. Molecular docking into HDAC crystal structures suggested a binding mode for these thiol derivatives consistent with the stereoselectivity observed upon insertion of amide-lactam substituents in the ?-position. ST7612AA1 (117), selected as a drug candidate for further development, showed an in vitro activity in the nanomolar range associated with a remarkable in vivo antitumor activity, highly competitive with the most potent HDAC inhibitors, currently under clinical trials. A preliminary study of PK and metabolism is also illustrated.

  DOI：

  10.1021/jm5008209

文献信息

• [EN] NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS<br/>[FR] NOUVEAUX DÉRIVÉS THIO PORTANT DES LACTAMES EN TANT QU'INHIBITEURS PUISSANTS D'HDAC, ET LEURS UTILISATIONS EN TANT QUE MÉDICAMENTS
  申请人：SIGMA TAU IND FARMACEUTI

  公开号：WO2013041480A1

  公开（公告）日：2013-03-28

  The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds.

  本发明涉及一种新型酰胺化合物（式I），以及其作为抗肿瘤和促凋亡剂的用途。该发明包括在医学上使用这些化合物，涉及癌症疾病以及其他需要抑制HDAC的疾病，以及含有这些化合物的药物组合物。
• NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS
  申请人：SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP2758371A1

  公开（公告）日：2014-07-30
• US8927533B2
  申请人：——

  公开号：US8927533B2

  公开（公告）日：2015-01-06